💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sacrosidase

CHEMBL1201487 Phase 4 承認済み Enzyme
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Sacrosidase is a liquid enzyme replacement therapy containing recombinant yeast sacrosidase (sucrase), used to treat congenital sucrase-isomaltase deficiency (CSID), a rare genetic disorder. It hydrolyzes dietary sucrose into fructose and glucose in the small intestinal brush border, replacing the deficient endogenous enzyme and allowing normal carbohydrate absorption. The enzyme is derived from Saccharomyces cerevisiae and administered orally with each meal.

作用機序

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Sacrosidase is a liquid enzyme replacement therapy containing recombinant yeast sacrosidase (sucrase), used to treat congenital sucrase-isomaltase deficiency (CSID), a rare genetic disorder. It hydrolyzes dietary sucrose into fructose and glucose in the small intestinal brush border, replacing the deficient endogenous enzyme and allowing normal carbohydrate absorption. The enzyme is derived from Saccharomyces cerevisiae and administered orally with each meal.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Sacrosidase is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201487. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.